Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2000-10-06
2003-02-11
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S651000, C514S726000, C514S763000, C564S316000, C564S317000, C564S323000, C568S660000, C568S611000, C585S428000
Reexamination Certificate
active
06518314
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to compounds that act, at physiologically-compatible levels, to impede the formation of amyloid in brain, including Alzheimer senile amyloid plaques in vivo. More specifically, the present invention relates to compounds that impede the transformation of dense microspheres (DMS) into amyloid. The invention also relates to methdology for the screening of compounds that possess this activity, and to treating cerebral amyloidosis by administering such compounds therapeutically.
2. Description of Related Art
There is no effective therapy for cerebral amyloidosis, which almost invariably has a fatal outcome following the onset of amyloid deposits. For example, Alzheimer's disease is estimated to be the fourth or fifth leading cause of death in North Americans.
A universally accepted indicator of cerebral amyloidosis is the accumulation of lesions, so-called “senile plaques,” that are comprised in large part of amyloid fibrils. Senile plaques are spherical, ranging from 10 to 200 &mgr;m in diameter, and are found occasionally in aged cerebral cortex (see below) but in larger numbers in Alzheimer-affected cortex.
Most specialists agree that reproduction of amyloid fibrils experimentally from precursor materials which are extracted, activated, or otherwise derived from human brain constitutes the best available evidence linking an agent or precursor to the progression of cerebral amyloidosis. Indeed, the literature has documented the use of such materials from human brain, normal and Alzheimer-affected, that are not already amyloid, and their transformation into amyloid.
Accordingly, a reliable indicator is available for compounds that might be effective in treating cerebral amyloidosis. In particular, it is possible to determine whether a given compound prevents the structural tansition of a brain-localized precursor to a &bgr;-pleated sheet conformation and thus prevent conversion to cerebral amyloid (i.e., that displays “anti-amyloid activity”) at physiologically acceptable levels of the active agent. See U.S. Pat. No. 5,231,170, the contents of which are incorporated by reference.
In a majority of cases, subjects with cerebral amyloidosis, including Alzheimer's patients, display symptoms on a quantitative basis. Blessed et al.,
Brit J. Psychiatry
114: 797-811 (1968); Tomlinson et al.,
J. Neurol. Sci.
7: 331-56 (1968); Tomlinson, B. E., et al.,
J. Neurol. Sci.
11: 205-42 (1970); Corsellis, MENTAL ILLNESS AND THE AGEING BRAIN, Oxford University Press, London (1962); Corsellis, “Ageing and the Dementias,” in GREENFIELD'S NEUROPATHOLOGY 796-848, Edward Arnold, London (1976). Elderly subjects who have a small number of senile plaques are asymptomatic and are categorized by some experts as preclinical, by others as presymptomatic, and by still other authorities as normal variants. In any event, the elderly brain apparently can have a low number of senile plaques and still be categorized as “normal.” When the amyloid plaque number is high, however, symptoms of dementia appear. Thus, treatment regimens that prevent the formation of amyloid plaques or that reduce the number or rate of formation of amyloid plaques are useful.
A microscopic structure, the so-called “dense microsphere” (DMS), is found in normal brain and in brain affected by Alzheimer's disease. See Averback,
Acta Neuropathol.
61: 148-52 (1983); results confirmed by Hara,
J. Neuropath. Exp. Neurol.
(1986). Evidence for the existence of dense microspheres comes from microscopic histological section studies of fixed whole brain tissue, where the dense microspheres are seen to have a proteinaceous central region (“DMS protein”) surrounded by continuous membrane (“DMS membrane”).
The extraction, purification, and characterization of isolated samples of DMS and the use of DMS material have been documented. See, for example, U.S. Pat. Nos. 4,919,915 and 4,816,416, the respective contents of which are incorporated by reference.
DMS disruption is believed to commence after individual DMS reach a threshold size in the elderly or Alzheimer group. Even DMS that have reached the threshold size are quite small, with diameters on the order of approximately 10 microns or less. When the DMS disrupt, constituent protein matter transforms and redistributes to occupy a tissue volume, (anywhere between 10 to 1,000 times larger than the precedent DMS), which comprises a much larger injury focus.
SUMMARY OF THE INVENTION
Preventing the disruption of DMS would prevent the formation of amyloid plaques. If DMS disruption can be curtailed, for example, by around 25% or more, cerebral amyloid formation, and its rate of formation, induced by DMS disruption also can be reduced or prevented. Thus, reducing the size of the injury foci associated with disrupted DMS would impede the formation of amyloid plaques, by reducing the number of DMS disruptions that may be caused by an initial disruption. In addition, reducing the persistence of injury and inflammation associated with DMS disruption, including, for example, increasing the digestion and removal of DMS material through the reticuloendothelial system, would prevent the formation of amyloid plaques or, at least, reduce the number and/or rate of formation of other, secondary DMS disruptions.
Accordingly, a need exists for an approach to preventing DMS disruption. A need also exists for a method to reduce the size of the tissue volume associated with disrupted DMS (injury foci). Furthermore, there is a need for a technique to reduce the persistence of inflammatory reaction brought about by DMS disruption, as well as for methods to increase the digestion and removal of DMS material through the reticuloendothelial system.
It therefore is an object of the present invention to provide a composition and a method that are useful in impeding DMS disruption and, hence, in treating cerebral amyloidosis, a condition characterized by the presence of abnormal amounts of amyloid &bgr;-protein associated plaques (senile plaques) and other amyloid deposits. It is an additional object to provide a screening approach for identifying compounds that are useful in impeding DMS disruption.
It is also an object of the present invention to provide a treatment for cerebral amyloidosis by the administration of a compound selected from a class of pharmaceutically active agents that have in common an ability to impede the disruption of intact DMS.
In accomplishing the foregoing objects, a method has been provided, in accordance with one aspect of the present invention, for treating cerebral amyloidosis, comprising the step of administering to a subject in need thereof, a pharmaceutically effective amount of a compound that impedes disruption of intact DMS by: (i) reducing the mean tissue volume of disrupted DMS; (ii) reducing the ratio of the number of inflammatory cells per DMS; or (iii) increasing the ratio of the number of macrophages containing disrupted DMS material per DMS, each when compared to controls. The compound impedes the dirsuption of intact DMS when administered, at an in-tissue concentration of about 10
−5
M or less, to an experimental animal or to a test preparation of human postmortem brain that has received an intracerebral injection of DMS. In one preferred embodiment, the compound thus administered impedes disruption of intact DMS by reducing the mean tissue volume of disrupted DMS material. The compound acts on DMS components in such a way that disrupted DMS in situ attain a significantly reduced diameter, volume of tissue occupied by the redistributed transformed DMS protein material, and associated injury foci, when compared to the diameter, volume of tissue occupied, and injury foci of disrupted DMS in an untreated subject or in a subject treated with an inactive agent.
In accordance with another aspect of the present invention, there is provided a composition for treating cerebral amyloidosis, comprising a pharmaceutically effective amount of a compound that impedes disruption of intact
Averback Paul
Beheshti Iraj
Ghanbari Hossein
Morse David
Foley & Lardner
Nymox Corporation
LandOfFree
Pharmaceutical agents that impede the initiation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical agents that impede the initiation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical agents that impede the initiation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3145261